Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 63 P1129 | DOI: 10.1530/endoabs.63.P1129

1Republican Specialized Scientific Practical Medical Center of Endocrinology, Tashkent, Uzbekistan; 2Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan; 3Center for the Scientific and Clinical Study of Endocrinology, Uzbekistan Public Health Ministry, Tashkent, Uzbekistan.


Aim: To study the course of clinical symptoms in women with prolactinomas.

Material and research methods: The study included the results of clinical examination and treatment of 73 patients with prolactin-secreting pituitary adenomas. In the main group, 84.9% (62 women) and 15.1% (11 men) aged from 17 to 74 years old, the average age was (38.5±12.6 years). All patients were divided into 2 groups depending on the size of the education. Group I consisted of 47 patients with microprolactinomas (tumor size up to 10 mm). Group II of 15 patients with macroprolactinomas (tumor size more than 10 mm).

Results: Analysis of the age gradation of the studied patients by sex showed that men have a peak in the incidence of 41–50 years, and women 21–30 years old, that is, the vast majority of both men (63.6%) and women (74.2%) refers to the active working age – 21–50 years.The average age of women is 37.6±13.0 years. If we consider the occurrence of adenomas by sex, then in men (72.1%) and women (64.5%) macroadenomas are significantly more common. The clinical manifestations of hyperprolactinemia in our cases were characterized as follows: neurological disorders were often observed in 28 (45.2%) patients with headache, dizziness, sleep disturbances, memory loss,, visual impairment in 10 (16.1%), metabolic disorders in 4 (6.45%) patients obesity, dyslipidemia, psycho-emotional disorders in 11 (17.7%) depression, asthenia, irritability and endocrine disorders caused by loss of other functions pituitary hypothyroidism in 19 (30.6%), diabetes insipidus in 2 (3.2%). In gynecological practice, pathologies accompanied by hyperprolactinemia are: dyshormonal diseases of the mammary gland (DGMG) in 17 (25.8%), hypogonadotropic amenorrhea in 25 (40.3%), premenstrual syndrome in 16 (25.8%), luteal phase insufficiency in 22 (35.5%), uterine myoma in 3 (4.8%), diencephalic puberty syndrome in 9 (14.5%), osteopenic syndrome in 6 (9.7%) patients.

Conclusion: Thus, with prolactinomas in women, neurological symptoms are more common, along with endocrine disorders.

Volume 63

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts